Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.
Ann Hematol. 2024 Jun;103(6):1833-1841. doi: 10.1007/s00277-024-05730-y. Epub 2024 Apr 13.
Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The standard first-line therapy for MM consists of a three-drug induction regimen based on immunomodulatory drugs and proteasome inhibitors combined with autologous stem cell transplantation. However, MM remains incurable; therefore, therapies for relapsed/refractory MM (RRMM) are emerging and evolving rapidly. This study aimed to summarize and review the results of RRMM trials over the past 5 years to provide a holistic overview and insights for practitioners in related fields and to provide additional ideas for clinical trialists. This study shows that daratumumab and isatuximab continue to significantly advance as treatment options. Additionally, novel antibody drugs, such as elotuzumab and selinexor, as well as bispecific antibodies, teclistamab and talquetamab, are currently undergoing clinical research with promising outcomes. However, chimeric antigen receptor-T cell therapy targeting B-cell maturation antigen remains the optimal approach for MM treatment.
由于新型药物和技术在过去 20 年中的应用，多发性骨髓瘤（MM）的治疗方法不断得到改进。MM 的标准一线治疗包括基于免疫调节剂和蛋白酶体抑制剂的三药诱导方案，联合自体干细胞移植。然而，MM 仍然无法治愈；因此，复发/难治性 MM（RRMM）的治疗方法正在不断涌现和快速发展。本研究旨在总结和回顾过去 5 年 RRMM 试验的结果，为相关领域的从业者提供全面的概述和见解，并为临床试验研究者提供更多的思路。本研究表明，达雷妥尤单抗和伊沙妥昔单抗继续作为治疗选择取得显著进展。此外，新型抗体药物，如埃罗妥珠单抗和塞利尼索，以及双特异性抗体，特莱西单抗和塔卢卡单抗，目前正在进行临床研究，结果有很大的希望。然而，嵌合抗原受体-T 细胞疗法针对 B 细胞成熟抗原仍然是 MM 治疗的最佳方法。
